Analyst Ami Fadia of Needham reiterated a Buy rating on Harmony Biosciences Holdings, retaining the price target of $42.00.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Ami Fadia has given his Buy rating due to a combination of factors, including the promising developments surrounding Harmony Biosciences Holdings’ pitolisant GR formulation. The company announced positive results from a pivotal bioequivalence study, indicating that the new formulation is equivalent to the existing Wakix in terms of efficacy, with improved tolerability. This advancement suggests that, upon approval, the new version could be introduced to the market without the need for dose titration, which is currently required for Wakix.
Ahead of significant catalysts expected in 2026, such as Phase 3 results for EPX-100 in Dravet Syndrome and Lennox-Gastaut Syndrome, as well as initial clinical data from BP1-15205, Fadia sees potential growth for Harmony Biosciences. The upcoming update from the open-label study for EPX-100 at the American Epilepsy Society further supports the positive outlook, reinforcing the Buy recommendation.
In another report released on November 13, Mizuho Securities also reiterated a Buy rating on the stock with a $0.00 price target.